Use of a non-specific immunomodulation therapy as a therapeutic vasculogenesis strategy in no-option critical limb ischemia patients.

[1]  H. Itoh,et al.  Potential use of endothelial progenitor cells for regeneration of the vasculature , 2009, Therapeutic advances in cardiovascular disease.

[2]  J. Shang,et al.  Beneficial effect of autologous transplantation of bone marrow stromal cells and endothelial progenitor cells on cerebral ischemia in rabbits , 2008, Neuroscience Letters.

[3]  P. Ponikowski,et al.  Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial , 2008, The Lancet.

[4]  M. Säemann,et al.  Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy , 2007, Annals of the rheumatic diseases.

[5]  K. Node,et al.  Mobilization of CD34-Positive Bone Marrow–Derived Cells After Coronary Stent Implantation: Impact on Restenosis , 2007, Circulation.

[6]  A. Zwergal,et al.  Ozonized Low Density Lipoprotein (ozLDL) Inhibits NF-&kgr;B and IRAK-1–Associated Signaling , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[7]  A. Balbarini,et al.  Is transcutaneous oxygen and carbon dioxide monitoring indispensable in short- and long-term therapeutic management of non-reconstructable lower critical limb ischemia? , 2006, Minerva cardioangiologica.

[8]  Rodney A. White,et al.  ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography , 2006, Circulation.

[9]  Frank Emmrich,et al.  Therapeutical potential of blood-derived progenitor cells in patients with peripheral arterial occlusive disease and critical limb ischaemia. , 2005, European heart journal.

[10]  S. Fichtlscherer,et al.  Reduced Number of Circulating Endothelial Progenitor Cells Predicts Future Cardiovascular Events: Proof of Concept for the Clinical Importance of Endogenous Vascular Repair , 2005, Circulation.

[11]  Kim D Janda,et al.  Evidence for Ozone Formation in Human Atherosclerotic Arteries , 2003, Science.

[12]  A. Quyyumi,et al.  Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. , 2003, The New England journal of medicine.

[13]  Arshed A. Quyyumi,et al.  Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk , 2003 .

[14]  P. Ridker,et al.  Novel clinical markers of vascular wall inflammation. , 2001, Circulation research.

[15]  J. Dormandy,et al.  The fate of patients with critical leg ischemia. , 1999, Seminars in vascular surgery.

[16]  J. Isner,et al.  Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. , 1999, The Journal of clinical investigation.

[17]  Hiroshi Takahashi,et al.  Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon , 1999, Nature Medicine.

[18]  Haruchika Masuda,et al.  Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization , 1999, Nature Medicine.

[19]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[20]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[21]  B. Ohlsson,et al.  Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-kappaB to DNA and the subsequent expression of tumor necrosis factor-alpha and interleukin-1beta in macrophages. , 1996, The Journal of clinical investigation.

[22]  T. Bunt,et al.  TcPO2 as an accurate predictor of therapy in limb salvage , 1996, Annals of vascular surgery.

[23]  R. Hobson,et al.  Transcutaneous oxygen (TcPO2) estimates probability of healing in the ischemic extremity. , 1996, The Journal of surgical research.

[24]  G. Torre-Amione,et al.  Novel therapies for heart failure: focus on anti-inflammatory strategies. , 2006, Congestive heart failure.

[25]  R. Rutherford,et al.  Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). , 2000, Journal of vascular surgery.

[26]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.